Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.

Krystal Biotech, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

$107.1 MILLION IN 4Q VYJUVEK REVENUE AND $730.3 MILLION SINCE U.S. LAUNCH FDA GRANTED RMAT TO KB707 FOR THE TREATMENT OF ADVANCED NSCLC AND FAST TRACK DESIGNATION TO KB111 FOR THE TREATMENT OF HHD STRONG BALANCE SHEET, ENDING THE QUARTER WITH $955.9 MILLION IN CASH AND INVESTMENTS PITTSBURGH, FEB. 17, 2026 (GLOBE NEWSWIRE) -- KRYSTAL BIOTECH, INC. (THE COMPANY) (NASDAQ: KRYS) TODAY REPORTED FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL YEAR ENDING DECEMBER 31, 2025 AND PROVIDED A BUSINESS UPDATE. IN 2025, KRYSTAL MADE MEANINGFUL PROGRESS ON OUR MISSION TO SERVE PATIENTS WITH DYSTROPHIC EPIDERMOLYSIS BULLOSA AROUND THE WORLD, WHILE CONTINUING TO BUILD THE GLOBAL INFRASTRUCTURE REQUIRED TO SCALE OUR IMPACT, SAID KRISH S.

KRYSTAL BIOTECH ANNOUNCES FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL AND OPERATING RESULTS

PITTSBURGH, FEB. 10, 2026 (GLOBE NEWSWIRE) -- KRYSTAL BIOTECH, INC. (THE COMPANY) (NASDAQ: KRYS) ANNOUNCED TODAY THAT IT WILL REPORT ITS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS ON TUESDAY, FEBRUARY 17, 2026, PRIOR TO THE OPEN OF U.S. MARKETS.

KRYSTAL BIOTECH TO REPORT FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS ON FEBRUARY 17, 2026

PRELIMINARY 4Q 2025 VYJUVEK NET REVENUE OF $106 MILLION TO $107 MILLION ROBUST CLINICAL PIPELINE WITH MULTIBILLION DOLLAR OPPORTUNITIES AND STRONG BALANCE SHEET FOR SUSTAINED GROWTH PITTSBURGH, JAN. 11, 2026 (GLOBE NEWSWIRE) -- KRYSTAL BIOTECH, INC . (THE COMPANY) (NASDAQ: KRYS) TODAY ANNOUNCED SELECTED PRELIMINARY UNAUDITED 2025 FINANCIAL RESULTS, INCLUDING FOURTH QUARTER AND FULL YEAR 2025 VYJUVEK NET PRODUCT REVENUE, AND OUTLINED THE COMPANY'S STRATEGIC VISION TO DRIVE THE NEXT STAGE OF GROWTH OF ITS RARE DISEASE BUSINESS.

KRYSTAL BIOTECH PROVIDES BUSINESS UPDATE AT 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

PITTSBURGH, NOV. 26, 2025 (GLOBE NEWSWIRE) -- KRYSTAL BIOTECH, INC . (THE COMPANY) (NASDAQ: KRYS) TODAY ANNOUNCED THAT THE COMPANY WILL PARTICIPATE IN THE 8TH ANNUAL EVERCORE HEALTHCARE CONFERENCE ON DECEMBER 3, 2025, IN MIAMI. KRISH S. KRISHNAN, CHAIRMAN AND CHIEF EXECUTIVE OFFICER, WILL TAKE PART IN A FIRESIDE CHAT SCHEDULED AT 10:00 AM ET AND HOST INVESTOR MEETINGS THROUGHOUT THE DAY.

KRYSTAL BIOTECH TO PRESENT AT 8TH ANNUAL EVERCORE HEALTHCARE CONFERENCE

REVISED LABEL ALLOWS TREATMENT OF DEB PATIENTS FROM BIRTH VYJUVEK CAN NOW BE APPLIED BY PATIENTS AND CAREGIVERS PITTSBURGH, SEPT. 15, 2025 (GLOBE NEWSWIRE) -- KRYSTAL BIOTECH, INC. (THE COMPANY) (NASDAQ: KRYS) ANNOUNCED TODAY THAT THE UNITED STATES FOOD AND DRUG ADMINISTRATION (FDA) APPROVED A LABEL UPDATE FOR VYJUVEK (BEREMAGENE GEPERPAVEC-SVDT) THAT EXPANDS THE VYJUVEK ELIGIBLE PATIENT POPULATION TO INCLUDE DYSTROPHIC EPIDERMOLYSIS BULLOSA (DEB) PATIENTS FROM BIRTH AND PROVIDES PATIENTS FULL FLEXIBILITY WITH RESPECT TO VYJUVEK APPLICATION AND MANAGING WOUND DRESSINGS.

KRYSTAL BIOTECH ANNOUNCES FDA APPROVAL OF UPDATED VYJUVEK LABEL

PITTSBURGH, AUG. 21, 2025 (GLOBE NEWSWIRE) -- KRYSTAL BIOTECH, INC. (THE COMPANY) (NASDAQ: KRYS), A COMMERCIAL-STAGE BIOTECHNOLOGY COMPANY, TODAY ANNOUNCED AN UPDATE ON DEVELOPMENT PLANS FOR KB707, THE COMPANY'S REDOSABLE IMMUNOTHERAPY DESIGNED TO DRIVE SUSTAINED, LOCALIZED EXPRESSION OF INTERLEUKIN-2 (IL-2) AND INTERLEUKIN-12 (IL-12) IN THE TUMOR MICROENVIRONMENT AND PROMOTE SYSTEMIC IMMUNE-MEDIATED TUMOR CLEARANCE FOLLOWING INHALED OR INTRATUMORAL DELIVERY TO SOLID TUMORS.

KRYSTAL BIOTECH ANNOUNCES UPDATE ON DEVELOPMENT PLANS FOR ONCOLOGY PROGRAM KB707 AND PRIORITIZATION OF INHALED KB707 FOR THE TREATMENT OF NON-SMALL CELL LUNG CANCER

VYJUVEK APPROVED FOR THE TREATMENT OF DEB FROM BIRTH WITH FLEXIBLE ADMINISTRATION OPTIONS INCLUDING HOME DOSING AND THE OPTION FOR ADMINISTRATION BY THE PATIENT OR THEIR FAMILY

KRYSTAL BIOTECH ANNOUNCES APPROVAL OF VYJUVEK BY JAPAN'S MINISTRY OF HEALTH, LABOUR AND WELFARE FOR THE TREATMENT OF DYSTROPHIC EPIDERMOLYSIS BULLOSA

KB304 DESIGNED TO DELIVER COLLAGEN AND ELASTIN TO RESTORE SKIN NATURALLY CONFERENCE CALL TO DISCUSS RESULTS SCHEDULED FOR THURSDAY, JULY 24, 2025 AT 4:30PM ET PITTSBURGH, JULY 24, 2025 (GLOBE NEWSWIRE) -- JEUNE AESTHETICS, INC. (JEUNE), A WHOLLY OWNED SUBSIDIARY OF KRYSTAL BIOTECH, INC. (KRYSTAL) (NASDAQ: KRYS) LEVERAGING KRYSTAL'S CLINICALLY VALIDATED GENE-DELIVERY PLATFORM TO FUNDAMENTALLY REVERSE THE BIOLOGY OF AGING SKIN, ANNOUNCED TODAY POSITIVE SAFETY AND EFFICACY RESULTS, INCLUDING SIGNIFICANT IMPROVEMENTS IN KEY SKIN AESTHETIC ATTRIBUTES SUCH AS WRINKLES AND ELASTICITY, IN PEARL-2, A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 1 STUDY EVALUATING KB304, FOR THE TREATMENT OF WRINKLES OF THE DCOLLET. MEANINGFUL AESTHETIC IMPROVEMENTS WERE REPORTED FOLLOWING KB304 TREATMENT WITH CLEAR AND STATISTICALLY SIGNIFICANT ADVANTAGES OVER PLACEBO AS EVALUATED BY BOTH THE INVESTIGATOR AND SUBJECTS USING THE GLOBAL AESTHETIC IMPROVEMENT SCALE (GAIS).

JEUNE ANNOUNCES POSITIVE RESULTS AND SIGNIFICANT AESTHETIC IMPROVEMENTS FROM PHASE 1 STUDY OF KB304 FOR MODERATE TO SEVERE WRINKLES OF THE DCOLLET

EYE DROP ADMINISTRATION OF KB801 DESIGNED TO ENABLE SUSTAINED EXPRESSION OF NGF IN THE FRONT OF THE EYE INVESTOR CALL AND WEBCAST TO BE HELD JULY 9 AT 8:30 AM ET TO DISCUSS PROGRAM AND TRIAL DESIGN PITTSBURGH, JULY 09, 2025 (GLOBE NEWSWIRE) -- KRYSTAL BIOTECH, INC. (THE COMPANY) (NASDAQ: KRYS) ANNOUNCED TODAY THAT THE FIRST PATIENT HAS BEEN DOSED IN ITS PHASE 1/2 CLINICAL TRIAL (EMERALD-1), A 2:1 RANDOMIZED, DOUBLE-MASKED, MULTICENTER, PLACEBO-CONTROLLED STUDY EVALUATING KB801 FOR THE TREATMENT OF NEUROTROPHIC KERATITIS (NK). OUR OPHTHALMOLOGY PIPELINE IS WELL UNDER WAY WITH THE DOSING OF OUR FIRST PATIENT IN EMERALD-1, ALONG WITH INITIATION OF OUR PHASE 3 IOLITE STUDY IN DEB, SAID SUMA KRISHNAN, PRESIDENT, RESEARCH & DEVELOPMENT, KRYSTAL BIOTECH, INC. UNTIL NOW, RAPID PROTEIN CLEARANCE RATES AND HIGH CELL TURNOVER IN THE FRONT OF THE EYE HAVE SEVERELY LIMITED THE THERAPEUTIC POTENTIAL OF BIOLOGICS AND GENE THERAPIES FOR THE TREATMENT OF CORNEAL EPITHELIAL DEFECTS AND OTHER FRONT OF THE EYE DISEASES.

KRYSTAL BIOTECH ANNOUNCES FIRST PATIENT DOSED IN PHASE 1/2 TRIAL OF KB801 FOR THE TREATMENT OF NEUROTROPHIC KERATITIS

INTRA-PATIENT, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED STUDY WITH CROSSOVER DESIGN REPEAT ADMINISTRATION UNDER COMPASSIONATE USE WAS PREVIOUSLY SHOWN TO BE WELL TOLERATED AND ASSOCIATED WITH FULL CORNEAL HEALING BY 3 MONTHS AS WELL AS SIGNIFICANT VISUAL ACUITY IMPROVEMENT FROM HAND MOTION TO 20/25 AT 8 MONTHS PITTSBURGH, JUNE 24, 2025 (GLOBE NEWSWIRE) --  KRYSTAL BIOTECH, INC. (THE COMPANY) (NASDAQ: KRYS) ANNOUNCED TODAY THAT THE FIRST PATIENT HAS BEEN DOSED IN ITS PHASE 3 CLINICAL TRIAL (IOLITE), AN INTRA-PATIENT, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED STUDY WITH CROSSOVER DESIGN EVALUATING KB803 FOR THE TREATMENT AND PREVENTION OF CORNEAL ABRASIONS IN DYSTROPHIC EPIDERMOLYSIS BULLOSA (DEB) PATIENTS. KB803 IS DESIGNED TO DELIVER TWO COPIES OF THE COL7A1 TRANSGENE TO THE CORNEAL EPITHELIUM AND ENABLE LOCAL TYPE VII COLLAGEN PRODUCTION IN THE FRONT OF THE EYE.

KRYSTAL BIOTECH ANNOUNCES FIRST PATIENT DOSED IN PHASE 3 CLINICAL TRIAL OF KB803 FOR THE TREATMENT AND PREVENTION OF CORNEAL ABRASIONS IN PATIENTS WITH DYSTROPHIC EPIDERMOLYSIS BULLOSA

Krystal Biotech, Inc.

KRYS

Price

Financial Reports

No items found.

Press Releases

Krystal Biotech, Inc.

KRYS.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

KRYS